课题基金 / 基金详情

Targeted Nuclear Drug Delivery for Cancer Chemotherapy

Targeted Nuclear Drug Delivery for Cancer Chemotherapy
癌症化疗的靶向核药物递送
批准号:
0753109
负责人:
Youqing Shen
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
Continuing Grant
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-01 至 2011-05-31

项目摘要

项目成果

Youqing Shen的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CBET-0753109ShenMost anticancer drugs are toxins that target nuclear DNA to cause its damage or topoisomerase inhibition to induce cell death (apoptosis). Cancer cells, however, efficiently limit drug entry to their nuclei via the cell-membrane?associated multidrug resistance and various intracellular drug resistance mechanisms. Current drug carriers can deliver drugs to the cytosol and thus circumvent the multidrug resistance, but the cytosolic drugs are still subject to the intracellular drug-resistance. The PI thereby proposes that delivery of DNA-toxins directly to the nuclei of cancer cells would overcome both of these resistance mechanisms, but no carrier is available for in vivo nuclear drug delivery. The objectives of this project are to synthesize cancer-targeted active nuclear localization drug-conjugates (ANLCs) for in vivo nuclear drug delivery. An ANLC is a water-soluble polymer- or dendrimer-based DNA-toxin carrier, which is functionalized with cancer-targeting groups and lysosome-activated nuclear localization signals (NLSs). The NLSs are inactive before reaching cancer cells and thus in the blood circulation its nonspecific internalization is inhibited. Once inside acidic late lysosomes, the NLSs are activated as fully functioning NLSs. DNA-targeting drugs are covalently bound to the carrier using an intracellular cleavable bond. Therefore, the designed ANLCs are expected to circulate in the bloodstream for a prolonged time to accumulate in cancer tissues, be quickly internalized by the cancer cells, and then be transferred to their lysosomes to activate the NLSs. The NLSs then lead the conjugates to escape from the lysosomes and enter the nucleus, where the conjugates release their drug. The project will develop effective cancer chemotherapies that can efficiently overcome cancer drug resistance. This interdisciplinary research will also provide opportunities to educate underrepresented students and graduate/undergraduate students, and will stimulate and excite them engaged in science and engineering.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rational Design of Degradable Polymers for Gene Delivery
  • 批准号:
    0705298
  • 项目类别:
    Continuing Grant
  • 资助金额:
    $37.5万
  • 财政年份:
    2007
  • 负责人:
    Youqing Shen
  • 依托单位:
Self-Assembling Polymers: Synthesis and Characterization
  • 批准号:
    0650608
  • 项目类别:
    Standard Grant
  • 资助金额:
    $15.0万
  • 财政年份:
    2007
  • 负责人:
    Youqing Shen
  • 依托单位:
Rational Design of Anticancer Drug Resistance Nanoparticles
  • 批准号:
    0401982
  • 项目类别:
    Standard Grant
  • 资助金额:
    $31.7万
  • 财政年份:
    2004
  • 负责人:
    Youqing Shen
  • 依托单位:
SGER: Template-Controlled Living Polymerization for Synthesis of Self-Assembling Polymers
  • 批准号:
    0352812
  • 项目类别:
    Standard Grant
  • 资助金额:
    $9.98万
  • 财政年份:
    2003
  • 负责人:
    Youqing Shen
  • 依托单位:
国内基金
海外基金
Nuclear speckles支架蛋白SRRM2调控染色质高级结构的形成机制及功能研究
  • 批准号:
    22ZR1412400
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2022
  • 负责人:
    胡士斌
  • 依托单位:
研究nuclear speckles对哺乳动物早期胚胎染色体高级结构重编程和胚胎发育的调控作用
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    柯玉文
  • 依托单位:
Mapping Quantum Chromodynamics by Nuclear Collisions at High and Moderate Energies
  • 批准号:
    11875153
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2018
  • 负责人:
    MARCO RUGGIERI
  • 依托单位: